CTC
ABUS icon

Central Trust Company’s Arbutus Biopharma ABUS Stock Holding History

Central Trust Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$309 – 1428
2024
Q2 		$309 Buy
+100
New +$300 ﹤0.01% 1382

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Central Trust Company's ABUS Position: Q3 2024 in Review

Central Trust Company sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 100 shares — an estimated $309 sold.

Central Trust Company first reported a position in ABUS in Q2 2024 and held it in 1 quarter. The position peaked at $309 in Q2 2024. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

  • Central Trust Company reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
  • Central Trust Company sold 100 Arbutus Biopharma shares in Q3 2024, an estimated $309.
  • Central Trust Company first reported a position in Arbutus Biopharma in Q2 2024 and held it in 1 quarter.
  • Central Trust Company's Arbutus Biopharma position peaked at $309 in Q2 2024.
  • 144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on Central Trust Company's 13F filing for Q3 2024, filed 22 Oct 2024.